MediLink Therapeutics (Suzhou) Co., Ltd., a Shangai, China-based company developing globally competitive conjugated drugs and building a differentiated proprietary ADC technology platform, completed a US$70m Series B financing.
This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highlight Capital (HLC), etc.
The new funding will support clinical development of the company’s new generation Antibody-Drug Conjugate (ADC) pipeline, as well as early discovery and development of novel conjugated drugs.
Established in 2020 by Dr. Tongtong Xue, CEO, MediLink focuses clinical drug development on unmet clinical needs, while establishing close collaborations with potential international partners. At present, the company has invented and patented several novel proprietary ADC linker-payload technologies. First program will start Phase I clinical trial in both China and the United States this year. In addition, the company has established collaboration with several partners using MediLink’s proprietary technology platform.